This review assessed the use of antiretroviral drug regimens to prevent human immunodeficiency virus (HIV)-negative people exposed to HIV in non-occupational settings from becoming HIV-positive. Only one relevant study was found and the authors concluded that there was insufficient evidence to assess the effectiveness of treatment. This conclusion is likely to be reliable.
Study selection
Randomised controlled trials (RCTs), controlled clinical trials, cohort studies, and case-control studies of post-exposure prophylaxis for HIV were eligible. Prospective observational studies were eligible for adverse event data. Post-exposure prophylaxis was an antiretroviral drug regimen administered for up to 28 days to HIV-negative people who may have been exposed to HIV through sexual contact, use of a potentially contaminated needle, or exposure to potentially contaminated biological fluid. Eligible comparators were no prophylaxis or a different prophylaxis regimen. Outcomes of interest were HIV seroconversion frequency (primary outcome), adverse effects of prophylaxis, adherence to treatment, health-related quality of life, and costs or cost-effectiveness.
The only study included for clinical effectiveness evaluated a 28-day course of a fixed-dose combination of zidovudine and lamivudine.
Two reviewers independently selected studies for inclusion. Any disagreements were resolved by consensus, with arbitration by a third reviewer if necessary.
Assessment of study quality
Validity was assessed on the criteria of randomisation, proper sampling, adequate sample size, objective outcomes, blind assessment, objective eligibility criteria, reporting of attrition, comparability of groups, and generalisability.
Two reviewers independently applied the validity criteria. Any disagreements were resolved by consensus, with arbitration by a third reviewer if necessary.
Data extraction
Two reviewers independently extracted data using standard forms. Any disagreements were resolved by consensus, with arbitration by a third reviewer if necessary.
Methods of synthesis
Studies included for adverse events and cost-effectiveness were synthesised using a narrative approach. Only one study met the inclusion criteria for clinical effectiveness, so synthesis was not possible.
